Eolo Pharma

Sunchales, Argentina Founded: 2017 • Age: 9 yrs
Developer of therapies for treating inflammation-related diseases

About Eolo Pharma

Eolo Pharma is a company based in Sunchales (Argentina) founded in 2017 by Virginia Lopez and Pia Garat.. Eolo Pharma has raised $4.5 million across 2 funding rounds from investors including CITES and Paul Elberse. Eolo Pharma offers products and services including MVD1 and NCE Library. Eolo Pharma operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.

  • Headquarter Sunchales, Argentina
  • Founders Virginia Lopez, Pia Garat
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $4.5 M (USD)

    in 2 rounds

  • Latest Funding Round
    $1.8 M (USD), Series A

    Feb 08, 2023

  • Investors
    CITES

    & 1 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Eolo Pharma

Eolo Pharma offers a comprehensive portfolio of products and services, including MVD1 and NCE Library. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Lead compound targeting obesity and related conditions

Collection of novel molecules for various health indications

People of Eolo Pharma
Headcount 1-10
Employee Profiles 3
Employee Profiles
People
Carlos Escande
Chief Scientific Officer
People
Carlos Batthyany
Founder & CMO @ Eolo Pharma
People
Pia Garat
Chief Executive Officer

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of Eolo Pharma

Eolo Pharma has successfully raised a total of $4.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $1.8 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $1.8M
  • First Round

    (31 Dec 2019)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Feb, 2023 Amount Series A - Eolo Pharma Valuation

investors

Dec, 2019 Amount Series A - Eolo Pharma Valuation Paul Elberse
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Eolo Pharma

Eolo Pharma has secured backing from 2 investors, including institutional and angel investors. Prominent investors backing the company include CITES and Paul Elberse. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Angel
Investor Description Founded Year Domain Location
-
Founded Year Domain Location

Paul Elberse

-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Eolo Pharma

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Eolo Pharma

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Eolo Pharma Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Eolo Pharma

Eolo Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Novel dermatologic therapies are developed for skin conditions.
domain founded_year HQ Location
Small molecule therapeutics for inflammatory diseases are developed.
domain founded_year HQ Location
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
domain founded_year HQ Location
Developer of immunotherapies to treat cancer and autoimmune disorders
domain founded_year HQ Location
GPCR drug discovery platform is developed for multiple diseases.
domain founded_year HQ Location
Therapeutics for allergic and inflammatory diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Eolo Pharma

Frequently Asked Questions about Eolo Pharma

When was Eolo Pharma founded?

Eolo Pharma was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Eolo Pharma located?

Eolo Pharma is headquartered in Sunchales, Argentina. It is registered at Sunchales, Santa Fe, Argentina.

Who is the current CEO of Eolo Pharma?

Pia Garat is the current CEO of Eolo Pharma. They have also founded this company.

Is Eolo Pharma a funded company?

Eolo Pharma is a funded company, having raised a total of $4.5M across 2 funding rounds to date. The company's 1st funding round was a Series A of $2.7M, raised on Dec 31, 2019.

What does Eolo Pharma do?

Eolo Pharma is developing therapies for treating inflammation-related diseases (autoinflammatory and autoimmune diseases). Their lead candidate, EOLO3, which is used to treat metabolic syndrome. The candidate is in phase I clinical trial. The other candidates are in the preclinical stage.

Who are the top competitors of Eolo Pharma?

Eolo Pharma's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.

What products or services does Eolo Pharma offer?

Eolo Pharma offers MVD1 and NCE Library.

Who are Eolo Pharma's investors?

Eolo Pharma has 2 investors. Key investors include CITES, and Paul Elberse.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available